BioSpace News Archive

Tango Therapeutics, Inc. today announced two recent senior management appointments: Marc Rudoltz, M.D., as Chief Medical Officer, and Doug Barry, J.D., as General Counsel.

Calithera Biosciences, Inc. today shared interim safety and efficacy results from a Phase 1b, randomized, double-blind, placebo-controlled, dose-escalation trial evaluating CB-280, the company’s investigational arginase inhibitor, in adults with cystic fibrosis (CF).

Marrone Bio Innovations, Inc. has submitted the regulatory packages for MBI-306 to the U.S. Environmental Protection Agency (EPA) and for MBI-206 to all three Brazilian regulatory authorities

Cabaletta Bio, Inc. today announced 28-day clinical data from the third dose cohort using 500 million DSG3-CAART cells in the DesCAARTes™ Phase 1 clinical trial for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer.

TELA Bio, Inc. today announced it has entered into a distribution agreement with Next Science granting TELA exclusive rights to sell and market Next Science’s proprietary antimicrobial surgical wash with XBIO ® technology.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors at ObesityWeek® 2021.

AstraZeneca is proud to announce contributions to 30 nonprofit, community-based organizations nationwide through the ACT on Health Equity: Community Solutions Challenge.

AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ)